Developer docs
API playgroundTry for free, no card

Search company profiles

Formycon

Full company profile

uuid0002rd7

Namestring
Formycon
Legal namestring
Formycon AG
Websiteurl
formycon.com
Company typeenum
Public
Founded yearint
2010
Descriptiontext

Formycon AG is a German, publicly listed (Frankfurt Prime Standard, FYB) independent developer of biosimilars founded in 2010 and headquartered in Planegg-Martinsried near Munich. The company operates across the full biosimilar value chain — from candidate selection and protein analytics through process development, clinical trials, and regulatory approval — and has converted that capability into three commercially approved products: FYB201 (ranibizumab, biosimilar to Lucentis) marketed as Ranivisio/CIMERLI/Nufymco, FYB202 (ustekinumab, biosimilar to Stelara) marketed as Otulfi/Fymskina, and FYB203 (aflibercept, biosimilar to Eylea) marketed as AHZANTIVE/Baiama, the last of which launched in Europe in May 2026 with a US launch scheduled for Q4 2026 following a settlement of patent litigation with Regeneron and Bayer. The pipeline contains four additional candidates, led by FYB206 (pembrolizumab/Keytruda biosimilar, positive Dahlia PK data in Q1 2026) and FYB208 (dupilumab/Dupixent biosimilar, analytical comparability milestone November 2025).

Formycon generates revenue through a partnership-led commercialization model rather than a direct salesforce: it licenses or supplies approved products to regional specialists — Teva, Klinge Biopharma, Fresenius Kabi, Coherus BioSciences in Europe and the US, Zydus (US/Canada), Lotus Pharmaceutical (APAC), MS Pharma (MENA), Actor Pharma (Australia), Megalabs (LATAM), Horus Pharma (select EU) — earning milestone payments on development and regulatory achievements, gross-profit share on launch, and direct revenue share on US sales of CIMERLI and Nufymco. The lead development asset, FYB201, is jointly developed with Bioeq AG under a 50% at-equity investment relationship. End customers are healthcare systems and patients requiring affordable biologic therapies in ophthalmology (wet AMD, DME, CNV, RVO), immunology (psoriasis, Crohn's, ulcerative colitis), and oncology (Keytruda-referenced indications).

For financial scale and governance, Formycon reported Q1 2026 revenue of EUR 13.1M (+147% YoY versus EUR 5.3M in Q1 2025), narrowed its Q1 2026 EBITDA loss to EUR -1.7M (from EUR -13.2M), and guided FY 2026 revenue to EUR 60-70M with an EBITDA range of EUR 0-10M — implying a transition to sustainable EBITDA profitability in 2026. Working capital stood at EUR 66.4M as of March 31, 2026 (EUR 70.1M at end-2025), supplemented by a EUR 82.84M strategic investment from Gedeon Richter in January 2024 (9.08% stake) and a 2025/2029 corporate bond. The shareholder structure is diversified: ATHOS KG ~24.3%, Wendeln & Cie. KG ~13.6%, Gedeon Richter ~9.0%, Active Ownership Corporations ~6.0%, DSP Beteiligungsgesellschaft ~5.0%, founders/management ~5.9%, and free float ~36.2%.

Short descriptiontext

Formycon AG is a Frankfurt-listed independent German biosimilar developer that takes candidates from protein analytics through regulatory approval and licenses them to regional partners (Teva, Zydus, Lotus, Coherus, Fresenius Kabi, MS Pharma) for global commercialization in ophthalmology, immunology, and oncology.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPlanegg, Germany
HQ citystring
Planegg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar development, biopharmaceutical manufacturing, protein analytics, biosimilar pipeline, biopharma partnerships
Industry1 code
PRIMARYHLAIAFAH
Growth Hormone Biosimilars
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biosimilars
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Milestone payments
TypeLicensing Royalties
Description

Formycon receives milestone payments from partners for development achievements including regulatory approvals, clinical milestones, and regional partnership signings. For example, Zydus partnership includes mid-teens-million-euro upfront and milestone payments plus mid-double-digit share of gross profits upon launch.

formycon.com
2Direct commercialization revenue
TypeTransaction Fee
Description

Revenue from direct participation in commercialization of approved biosimilars. For FYB201, Formycon receives direct revenue share from US market (CIMERLI/Nufymco brands). For FYB202, revenue from direct participation in marketing.

formycon.com
3Profit sharing from partnerships
TypeLicensing Royalties
Description

Formycon receives a share of gross profits from commercialization partners upon product launch. The Zydus deal includes mid-double-digit percentage share of gross profits for FYB206 in US/Canada.

formycon.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Ranivisio
Description

Brand name for FYB201/Ranibizumab biosimilar in certain markets

medinfo.formycon.com
+3 more records
Core offering1 text field

Formycon is an independent developer of high-quality biosimilars, covering the entire value chain from biosimilar candidate selection through analytical development, clinical trials, regulatory approval, and delivery of market-ready products. The company develops ranibizumab (Lucentis biosimilar), ustekinumab (Stelara biosimilar), aflibercept (Eylea biosimilar), and pembrolizumab (Keytruda biosimilar) candidates for ophthalmology, immunology, and oncology indications, commercializing through regional pharmaceutical partners worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Global biosimilar market expected to grow from ~$21 billion to over $74 billion by 2030
+2 more records
Product overview1 text field

Formycon AG is a leading independent developer of high-quality biosimilars covering the entire value chain from biosimilar candidate selection through development to approved, market-ready products. The company has three approved biosimilars on the market: FYB201/Ranibizumab (biosimilar to Lucentis), FYB202/Ustekinumab (biosimilar to Stelara), and FYB203/Aflibercept (biosimilar to Eylea). Four additional biosimilar candidates are in development including FYB206/Pembrolizumab (Keytruda biosimilar), FYB208/Dupilumab (Dupixent biosimilar), FYB209, and FYB210. The company operates a multi-partner commercialization model, partnering with companies including Teva, Klinge Biopharma, Fresenius Kabi, Bioeq, and others for global distribution. Products target therapies in ophthalmology (anti-VEGF treatments) and immunology (autoimmune diseases). Formycon also provides a medical information portal (MedInfo) for patients and healthcare professionals.

Product and service7 records
1FYB201 (Ranibizumab)
CategoryApproved Biosimilar
Description

Biosimilar to Lucentis (ranibizumab) for treating retinal diseases including wet AMD, DME, CNV, and RVO. Marketed as CIMERLI (Coherus BioSciences) and Nufymco (Formycon) in the US, and as Ranivisio in Europe through Teva and Fresenius Kabi.

2FYB202 (Ustekinumab)
CategoryApproved Biosimilar
Description

Biosimilar to Stelara (ustekinumab) for treating psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Available as Otulfi (Fresenius Kabi) and Fymskina (Formycon) in various markets, in 45mg/90mg pre-filled syringes and 130mg concentrate for infusion.

3FYB203 (Aflibercept)
CategoryApproved Biosimilar
Description

Biosimilar to Eylea (aflibercept) for treating serious retinal diseases including wet AMD, DME, CNV, and RVO. Marketed as AHZANTIVE and Baiama in Europe by Klinge Biopharma GmbH; US launch expected Q4 2026.

4FYB206 (Pembrolizumab)
CategoryBiosimilar Candidate
Description

Biosimilar candidate to Keytruda (pembrolizumab) for oncology indications including melanoma, NSCLC, and other cancers. Development nearing completion with positive pharmacokinetic equivalence data demonstrating comparability to reference drug.

5FYB208 (Dupilumab)
CategoryBiosimilar Candidate
Description

Biosimilar candidate for Dupixent (dupilumab) targeting chronic inflammatory diseases including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Demonstrated high analytical comparability to reference drug.

6FYB209
CategoryBiosimilar Candidate
Description

Biosimilar candidate in Formycon's development pipeline.

7FYB210
CategoryBiosimilar Candidate
Description

Biosimilar candidate in Formycon's development pipeline.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
1Lotus Pharmaceutical
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-11
Description

Exclusive license agreement for FYB206 (pembrolizumab biosimilar) covering major parts of Asia-Pacific region. Formycon receives upfront payment, contingent milestone payments, and share of gross profits. Builds on prior collaboration for aflibercept biosimilar AHZANTIVE.

jdsupra.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-09
Description

Exclusive licensing and supply agreement for FYB206 (pembrolizumab biosimilar) in US and Canada. Formycon develops, registers, manufactures and supplies; Zydus handles commercialization. Deal includes mid-teens-million-euro upfront and milestone payments with mid-double-digit share of gross profits upon launch.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-04
Description

Exclusive licensing and supply agreement for commercialization of FYB206 (Keytruda biosimilar) in Middle East and North Africa region. Collaboration aims to increase access to cancer drug with potential for future expansion and technology transfer.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Semi-exclusive commercialization agreement for AHZANTIVE (aflibercept biosimilar) in Europe. Settlement with Regeneron and Bayer secured European market entry for AHZANTIVE and Baiama beginning May 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Launched AHZANTIVE (aflibercept biosimilar) in Europe in May 2026 across France, Germany, Spain, and Netherlands with plans to expand. Teva is executing its 'Pivot to Growth' strategy with this biosimilar launch.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

50% at-equity investment partner for FYB201 (ranibizumab biosimilar). Joint development partner with Formycon for Lucentis biosimilar. Development and commercialization collaboration for FYB201 and other biosimilar products.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Commercialization partner for FYB202 (Stelara biosimilar) marketed as Otulfi in select countries. Also involved in launching Ranivisio, the first Lucentis biosimilar in Europe.

8Actor Pharma
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Licensing agreement for aflibercept biosimilar commercialization in Australia.

gabionline.net
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Licensing agreement for aflibercept biosimilar commercialization in Latin America.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Licensing agreement for aflibercept biosimilar commercialization in selected European countries.

Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Commercialization partner for CIMERLI brand of ranibizumab biosimilar FYB201 in US market. Formycon re-entered US market with CIMERLI in Q1 2026 with Nufymco brand planned for H2 2026.

Strategic tierMinorTypeOthers
Description

Settled all patent disputes regarding EU-approved aflibercept biosimilars AHZANTIVE and BAIAMA referencing Eylea. Biosimilars may be launched in Europe and other markets beginning May 2026. US litigation separately settled with Q4 2026 US launch date.

Strategic tierMinorTypeOthers
Description

Settled European patent disputes with Formycon and Klinge Biopharma regarding aflibercept biosimilars AHZANTIVE and Baiama, enabling May 2026 European market entry.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

South Korean biosimilar developer with multiple approved products across immunology (Remsima, Truxima, Herzuma) and oncology - directly comparable as a pure-play biosimilar developer competing for share on overlapping reference molecules.

TypeDirect peer
Description

South Korean biosimilar developer with approved products for Eylea (Opuviz), Lucentis (Byooviz), Stelara (Pyzchiva), and others. Directly overlaps with Formycon's portfolio across ophthalmology and immunology reference products.

TypeDirect peer
Description

Iceland-based biosimilar developer with approved biosimilars for Eylea (Yesafili), Stelara (Selarsdi), and others. Direct competitor across multiple reference molecules targeted by Formycon.

TypeDirect peer
Description

India-based global biosimilar developer with approved biosimilars across oncology, immunology, and ophthalmology. Direct peer operating with similar therapeutic-area focus and partnership-driven commercialization in many markets.

TypeDirect peer
Description

Swiss biosimilar developer and 50% at-equity joint venture partner of Formycon. Co-develops FYB201 and shares development and commercialization responsibilities - direct peer with substantial operational overlap.

TypeDirect peer
Description

US-based biosimilar developer and Formycon's commercialization partner for CIMERLI. Operates its own biosimilar portfolio (Cimerli, Udenyca, Yusimry) - directly comparable and operationally intertwined through the partnership.

7Sandoz (Novartis)
TypeBroad incumbent
Description

Largest global biosimilar business with a broad portfolio across immunology, ophthalmology, and oncology. Established market leader whose scale and commercial reach Formycon competes against in target markets.

TypeBroad incumbent
Description

Major biologic manufacturer with biosimilars (Amjevita, Mvasi, Kanjinti) alongside proprietary biologics. Competes with Formycon's biosimilars while operating at materially greater scale and scope.

TypeRegional player
Description

German-headquartered pharmaceutical company with a biosimilar portfolio including Eylea (via Alvotech partnership) and Stelara biosimilars. Operates in the same European markets as Formycon with comparable product overlap.

TypeDirect peer
Description

Spanish biosimilar developer focused on oncology and immunology. Direct peer developing and commercializing biosimilars across similar therapeutic categories as Formycon with comparable scale and partnership-led business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Formycon

Biosimilarsformycon.com

Formycon AG is a Frankfurt-listed independent German biosimilar developer that takes candidates from protein analytics through regulatory approval and licenses them to regional partners (Teva, Zydus, Lotus, Coherus, Fresenius Kabi, MS Pharma) for global commercialization in ophthalmology, immunology, and oncology.

What Formycon does

Formycon AG is a German, publicly listed (Frankfurt Prime Standard, FYB) independent developer of biosimilars founded in 2010 and headquartered in Planegg-Martinsried near Munich. The company operates across the full biosimilar value chain — from candidate selection and protein analytics through process development, clinical trials, and regulatory approval — and has converted that capability into three commercially approved products: FYB201 (ranibizumab, biosimilar to Lucentis) marketed as Ranivisio/CIMERLI/Nufymco, FYB202 (ustekinumab, biosimilar to Stelara) marketed as Otulfi/Fymskina, and FYB203 (aflibercept, biosimilar to Eylea) marketed as AHZANTIVE/Baiama, the last of which launched in Europe in May 2026 with a US launch scheduled for Q4 2026 following a settlement of patent litigation with Regeneron and Bayer. The pipeline contains four additional candidates, led by FYB206 (pembrolizumab/Keytruda biosimilar, positive Dahlia PK data in Q1 2026) and FYB208 (dupilumab/Dupixent biosimilar, analytical comparability milestone November 2025).

Formycon generates revenue through a partnership-led commercialization model rather than a direct salesforce: it licenses or supplies approved products to regional specialists — Teva, Klinge Biopharma, Fresenius Kabi, Coherus BioSciences in Europe and the US, Zydus (US/Canada), Lotus Pharmaceutical (APAC), MS Pharma (MENA), Actor Pharma (Australia), Megalabs (LATAM), Horus Pharma (select EU) — earning milestone payments on development and regulatory achievements, gross-profit share on launch, and direct revenue share on US sales of CIMERLI and Nufymco. The lead development asset, FYB201, is jointly developed with Bioeq AG under a 50% at-equity investment relationship. End customers are healthcare systems and patients requiring affordable biologic therapies in ophthalmology (wet AMD, DME, CNV, RVO), immunology (psoriasis, Crohn's, ulcerative colitis), and oncology (Keytruda-referenced indications).

For financial scale and governance, Formycon reported Q1 2026 revenue of EUR 13.1M (+147% YoY versus EUR 5.3M in Q1 2025), narrowed its Q1 2026 EBITDA loss to EUR -1.7M (from EUR -13.2M), and guided FY 2026 revenue to EUR 60-70M with an EBITDA range of EUR 0-10M — implying a transition to sustainable EBITDA profitability in 2026. Working capital stood at EUR 66.4M as of March 31, 2026 (EUR 70.1M at end-2025), supplemented by a EUR 82.84M strategic investment from Gedeon Richter in January 2024 (9.08% stake) and a 2025/2029 corporate bond. The shareholder structure is diversified: ATHOS KG ~24.3%, Wendeln & Cie. KG ~13.6%, Gedeon Richter ~9.0%, Active Ownership Corporations ~6.0%, DSP Beteiligungsgesellschaft ~5.0%, founders/management ~5.9%, and free float ~36.2%.

Formycon firmographics

Firmographics
Name
Formycon
Legal name
Formycon AG
Website
https://formycon.com
Company type
Public
Founded year
2010
Operating status
Operating
Headcount range
101–250 employees
Short description
Formycon AG is a Frankfurt-listed independent German biosimilar developer that takes candidates from protein analytics through regulatory approval and licenses them to regional partners (Teva, Zydus, Lotus, Coherus, Fresenius Kabi, MS Pharma) for global commercialization in ophthalmology, immunology, and oncology.
Ownership category
akta.pro rank

Formycon industry classification

Industry
Product category
Biosimilars
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAFAH
Growth Hormone Biosimilars

Keywords

  • Biosimilar development
  • Biopharmaceutical manufacturing
  • Protein analytics
  • Biosimilar pipeline
  • Biopharma partnerships

Where Formycon is headquartered

Location

Headquarters

HQ city
Planegg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Formycon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Milestone payments: Formycon receives milestone payments from partners for development achievements including regulatory approvals, clinical milestones, and regional partnership signings. For example, Zydus partnership includes mid-teens-million-euro upfront and milestone payments plus mid-double-digit share of gross profits upon launch.
  2. Direct commercialization revenue: Revenue from direct participation in commercialization of approved biosimilars. For FYB201, Formycon receives direct revenue share from US market (CIMERLI/Nufymco brands). For FYB202, revenue from direct participation in marketing.
  3. Profit sharing from partnerships: Formycon receives a share of gross profits from commercialization partners upon product launch. The Zydus deal includes mid-double-digit percentage share of gross profits for FYB206 in US/Canada.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels6 records

Formycon product offering

Product offering

Core offering

Formycon is an independent developer of high-quality biosimilars, covering the entire value chain from biosimilar candidate selection through analytical development, clinical trials, regulatory approval, and delivery of market-ready products. The company develops ranibizumab (Lucentis biosimilar), ustekinumab (Stelara biosimilar), aflibercept (Eylea biosimilar), and pembrolizumab (Keytruda biosimilar) candidates for ophthalmology, immunology, and oncology indications, commercializing through regional pharmaceutical partners worldwide.

Product overview

Formycon AG is a leading independent developer of high-quality biosimilars covering the entire value chain from biosimilar candidate selection through development to approved, market-ready products. The company has three approved biosimilars on the market: FYB201/Ranibizumab (biosimilar to Lucentis), FYB202/Ustekinumab (biosimilar to Stelara), and FYB203/Aflibercept (biosimilar to Eylea). Four additional biosimilar candidates are in development including FYB206/Pembrolizumab (Keytruda biosimilar), FYB208/Dupilumab (Dupixent biosimilar), FYB209, and FYB210. The company operates a multi-partner commercialization model, partnering with companies including Teva, Klinge Biopharma, Fresenius Kabi, Bioeq, and others for global distribution. Products target therapies in ophthalmology (anti-VEGF treatments) and immunology (autoimmune diseases). Formycon also provides a medical information portal (MedInfo) for patients and healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

  • Ranivisio: Brand name for FYB201/Ranibizumab biosimilar in certain markets
  • Fymskina
  • Nufymco
  • CIMERLI

Products and services

  • FYB201 (Ranibizumab) Biosimilar to Lucentis (ranibizumab) for treating retinal diseases including wet AMD, DME, CNV, and RVO. Marketed as CIMERLI (Coherus BioSciences) and Nufymco (Formycon) in the US, and as Ranivisio in Europe through Teva and Fresenius Kabi.
  • FYB202 (Ustekinumab) Biosimilar to Stelara (ustekinumab) for treating psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Available as Otulfi (Fresenius Kabi) and Fymskina (Formycon) in various markets, in 45mg/90mg pre-filled syringes and 130mg concentrate for infusion.
  • FYB203 (Aflibercept) Biosimilar to Eylea (aflibercept) for treating serious retinal diseases including wet AMD, DME, CNV, and RVO. Marketed as AHZANTIVE and Baiama in Europe by Klinge Biopharma GmbH; US launch expected Q4 2026.
  • FYB206 (Pembrolizumab) Biosimilar candidate to Keytruda (pembrolizumab) for oncology indications including melanoma, NSCLC, and other cancers. Development nearing completion with positive pharmacokinetic equivalence data demonstrating comparability to reference drug.
  • FYB208 (Dupilumab) Biosimilar candidate for Dupixent (dupilumab) targeting chronic inflammatory diseases including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Demonstrated high analytical comparability to reference drug.
  • FYB209 Biosimilar candidate in Formycon's development pipeline.
  • FYB210 Biosimilar candidate in Formycon's development pipeline.

Quantifiable outcome

  • Global biosimilar market expected to grow from ~$21 billion to over $74 billion by 2030
  • +2 more outcomes

Companies that use Formycon

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Formycon technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Formycon partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, major and minor.

  • Lotus PharmaceuticalcoreChannel Partner/ Reseller/ Distributor · 11 February 2026Exclusive license agreement for FYB206 (pembrolizumab biosimilar) covering major parts of Asia-Pacific region. Formycon receives upfront payment, contingent milestone payments, and share of gross profits. Builds on prior collaboration for aflibercept biosimilar AHZANTIVE.
  • Zydus LifesciencescoreChannel Partner/ Reseller/ Distributor · 9 December 2025Exclusive licensing and supply agreement for FYB206 (pembrolizumab biosimilar) in US and Canada. Formycon develops, registers, manufactures and supplies; Zydus handles commercialization. Deal includes mid-teens-million-euro upfront and milestone payments with mid-double-digit share of gross profits upon launch.
  • MS PharmamajorChannel Partner/ Reseller/ Distributor · 4 December 2025Exclusive licensing and supply agreement for commercialization of FYB206 (Keytruda biosimilar) in Middle East and North Africa region. Collaboration aims to increase access to cancer drug with potential for future expansion and technology transfer.
  • Klinge Biopharma GmbHcoreChannel Partner/ Reseller/ DistributorSemi-exclusive commercialization agreement for AHZANTIVE (aflibercept biosimilar) in Europe. Settlement with Regeneron and Bayer secured European market entry for AHZANTIVE and Baiama beginning May 2026.
  • Teva Pharmaceutical IndustriescoreChannel Partner/ Reseller/ DistributorLaunched AHZANTIVE (aflibercept biosimilar) in Europe in May 2026 across France, Germany, Spain, and Netherlands with plans to expand. Teva is executing its 'Pivot to Growth' strategy with this biosimilar launch.
  • Bioeq AGcoreStrategic or Co-development Partner50% at-equity investment partner for FYB201 (ranibizumab biosimilar). Joint development partner with Formycon for Lucentis biosimilar. Development and commercialization collaboration for FYB201 and other biosimilar products.
  • Fresenius KabimajorChannel Partner/ Reseller/ DistributorCommercialization partner for FYB202 (Stelara biosimilar) marketed as Otulfi in select countries. Also involved in launching Ranivisio, the first Lucentis biosimilar in Europe.
  • Actor PharmaminorChannel Partner/ Reseller/ DistributorLicensing agreement for aflibercept biosimilar commercialization in Australia.
  • MegalabsminorChannel Partner/ Reseller/ DistributorLicensing agreement for aflibercept biosimilar commercialization in Latin America.
  • Horus PharmaminorChannel Partner/ Reseller/ DistributorLicensing agreement for aflibercept biosimilar commercialization in selected European countries.
  • Coherus BioSciencesmajorChannel Partner/ Reseller/ DistributorCommercialization partner for CIMERLI brand of ranibizumab biosimilar FYB201 in US market. Formycon re-entered US market with CIMERLI in Q1 2026 with Nufymco brand planned for H2 2026.
  • Regeneron PharmaceuticalsminorOthersSettled all patent disputes regarding EU-approved aflibercept biosimilars AHZANTIVE and BAIAMA referencing Eylea. Biosimilars may be launched in Europe and other markets beginning May 2026. US litigation separately settled with Q4 2026 US launch date.
  • BayerminorOthersSettled European patent disputes with Formycon and Klinge Biopharma regarding aflibercept biosimilars AHZANTIVE and Baiama, enabling May 2026 European market entry.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Formycon competitors and assessment

Company assessment

Direct peers

  • Celltrion: South Korean biosimilar developer with multiple approved products across immunology (Remsima, Truxima, Herzuma) and oncology - directly comparable as a pure-play biosimilar developer competing for share on overlapping reference molecules.
  • Samsung Bioepis: South Korean biosimilar developer with approved products for Eylea (Opuviz), Lucentis (Byooviz), Stelara (Pyzchiva), and others. Directly overlaps with Formycon's portfolio across ophthalmology and immunology reference products.
  • Alvotech: Iceland-based biosimilar developer with approved biosimilars for Eylea (Yesafili), Stelara (Selarsdi), and others. Direct competitor across multiple reference molecules targeted by Formycon.
  • Biocon Biologics: India-based global biosimilar developer with approved biosimilars across oncology, immunology, and ophthalmology. Direct peer operating with similar therapeutic-area focus and partnership-driven commercialization in many markets.
  • Bioeq AG: Swiss biosimilar developer and 50% at-equity joint venture partner of Formycon. Co-develops FYB201 and shares development and commercialization responsibilities - direct peer with substantial operational overlap.
  • Coherus BioSciences: US-based biosimilar developer and Formycon's commercialization partner for CIMERLI. Operates its own biosimilar portfolio (Cimerli, Udenyca, Yusimry) - directly comparable and operationally intertwined through the partnership.
  • Mabxience: Spanish biosimilar developer focused on oncology and immunology. Direct peer developing and commercializing biosimilars across similar therapeutic categories as Formycon with comparable scale and partnership-led business model.

Broad incumbents

  • Sandoz (Novartis): Largest global biosimilar business with a broad portfolio across immunology, ophthalmology, and oncology. Established market leader whose scale and commercial reach Formycon competes against in target markets.
  • Amgen: Major biologic manufacturer with biosimilars (Amjevita, Mvasi, Kanjinti) alongside proprietary biologics. Competes with Formycon's biosimilars while operating at materially greater scale and scope.

Regional players

  • Stada Arzneimittel: German-headquartered pharmaceutical company with a biosimilar portfolio including Eylea (via Alvotech partnership) and Stelara biosimilars. Operates in the same European markets as Formycon with comparable product overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Formycon social profiles

Digital presence

Formycon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Formycon leadership team

Management profile

Number of profiles

Profiles10 records

Formycon subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Formycon funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Formycon M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Formycon

What does Formycon do?

Formycon is an independent developer of high-quality biosimilars, covering the entire value chain from biosimilar candidate selection through analytical development, clinical trials, regulatory approval, and delivery of market-ready products. The company develops ranibizumab (Lucentis biosimilar), ustekinumab (Stelara biosimilar), aflibercept (Eylea biosimilar), and pembrolizumab (Keytruda biosimilar) candidates for ophthalmology, immunology, and oncology indications, commercializing through regional pharmaceutical partners worldwide.

Is Formycon a public or private company?

Formycon is a public company. It is classified as public and is currently operating.

When was Formycon founded?

Formycon was founded in 2010. It employs 101 to 250 people.

Where is Formycon based?

Formycon is headquartered in Planegg, Germany, in the Europe region.

How does Formycon make money?

Three revenue lines are on record. Milestone payments are the primary driver. The others are direct commercialization revenue and profit sharing from partnerships.

Who are Formycon's main competitors?

Direct peers on record are Celltrion, Samsung Bioepis, Alvotech, Biocon Biologics, Bioeq AG, Coherus BioSciences and Mabxience. Broad incumbents are Sandoz (Novartis) and Amgen. Stada Arzneimittel is listed as a regional player.

Does Formycon have an API?

No public API is recorded for Formycon.

What industry is Formycon in?

Formycon's product category is Biosimilars. Its primary akta.pro industry code is HLAIAFAH, Growth Hormone Biosimilars. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deEQS-News: Formycon AG: Zwei Blockbuster, zwei Niche-Buster, ein Smart Portfolio: Formycon nennt Tezspire und Hemlibra als ReferenzarzneimittelFormycon AG named Tezepelumab (Tezspire) and Emicizumab (Hemlibra) as reference drugs for its biosimilar candidates FYB210 and FYB286. Tezspire's global sales rose 50% to $1.9 billion in 2025, while Hemlibra's rose 11% to $5.7 billion. The company also has a biosimilar to Keytruda (FYB206) awaiting FDA approval.The future of tradingFormycon names Tezspire, Hemlibra as reference drugs for biosimilar candidatesFormycon identified Tezspire and Hemlibra as reference drugs for two biosimilar candidates in early development. Tezspire sales rose 50% to $1.9 billion in 2025, while Hemlibra sales rose 11% to CHF 4.8 billion. Biocelys provides manufacturing for FYB286, with Santo Biosimilar financing development.Seeking AlphaFormycon AG (FYBGF) Q3 2026 Earnings Call TranscriptFormycon AG reported its Q3 2026 results, with financial performance improving substantially year-on-year. The company also announced an impairment last week, which it will explain in the call. The call will cover how market learnings are incorporated into its strategy and next-generation portfolio.TradingViewFYB: Revenue doubled and EBITDA improved, but impairments deepened the net lossFormycon AG reported FYB revenue of €40.0m, more than double the prior year, and EBITDA loss narrowed to €8.9m. Non-cash valuation charges widened the net loss, and adjusted EBITDA guidance moved to a loss. Core guidance for 2026 was maintained at the lower ends of ranges.TradingViewFYB: Revenue doubled, FYB206 advanced, and non-cash impairments reset the earnings outlookFormycon AG reported revenue doubled to €40.0 million and EBITDA losses narrowed, while non-cash impairments are expected to reduce 2026 net result by about €121 million. The company's FYB206 BLA was accepted for FDA review, and adjusted EBITDA guidance was cut to €-15 million to €-5 million.Business & FinancialFormycon Doubles Nine-Month Revenue And Consistently Advances Implementation Of Its Fyb4growth StrategyFormycon AG reported consolidated revenue of €40.0 million for the first nine months of 2026, doubling the prior-year €19.5 million. The FDA accepted the BLA for its pembrolizumab biosimilar FYB206, and the company revised its adjusted EBITDA outlook to €-15 million to €-5 million.FinanzNachrichten.deANLEIHEN-Woche KW45: Homann, Formycon, ESV, The Grounds, hep, PNE, Energiekontor, EPH Group, Algene, The Platform Group, BOOSTER Precision, medondo, Score Capital, Mutares, POB, WeGrow, LAIQON, FinexiMultiple bond issuers reported Q3 results and revised 2026 forecasts, including Homann's revenue beat and ESV's new 8% bond. Formycon and BOOSTER Precision cut their EBITDA guidance, while POB adjusted its revenue outlook. The company also announced a new bond offering.FinanzNachrichten.deFormycon nimmt Wertberichtigungen auf FYB201 und FYB202 vorFormycon is recognizing impairment charges for its biosimilars FYB201 and FYB202 due to rising price pressure. The charges total €121 million for the 2026 consolidated result, with €82 million for FYB202 and €39 million for FYB201, reflecting reduced sales expectations from marketing partners.FinanzNachrichten.deFormycon senkt Prognose für bereinigtes EBITDA deutlichFormycon AG revised its 2026 adjusted EBITDA forecast to a range of -15 to -5 million euros, down from 5 to 15 million euros. The change reflects lower sales expectations from marketing partners for biosimilars FYB201 and FYB202, affecting its stake in Bioeq. Other forecasts remain unchanged.Business & FinancialFormycon Maintains 2026 Guidance For Revenue, EBITDA And Working Capital, Revises Adjusted EBITDA And Reassesses FYB201 And FYB202Formycon AG maintained its 2026 revenue, EBITDA, and working capital guidance but revised adjusted EBITDA to a negative range due to lower revenue expectations for its ranibizumab and ustekinumab products. The company recognized non-cash impairments of EUR 82 million and EUR 39 million on those products, with no cash outflow.